A detailed history of Rafferty Asset Management, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 470,572 shares of GILD stock, worth $42.4 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
470,572
Previous 596,197 21.07%
Holding current value
$42.4 Million
Previous $40.9 Million 3.57%
% of portfolio
0.14%
Previous 0.15%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$66.59 - $83.99 $8.37 Million - $10.6 Million
-125,625 Reduced 21.07%
470,572 $39.4 Million
Q2 2024

Aug 13, 2024

BUY
$63.15 - $72.88 $11.1 Million - $12.9 Million
176,519 Added 42.06%
596,197 $40.9 Million
Q1 2024

May 13, 2024

BUY
$71.58 - $87.29 $3.19 Million - $3.89 Million
44,530 Added 11.87%
419,678 $30.7 Million
Q4 2023

Feb 13, 2024

BUY
$73.27 - $83.09 $1.22 Million - $1.38 Million
16,626 Added 4.64%
375,148 $30.4 Million
Q3 2023

Nov 13, 2023

BUY
$73.94 - $80.67 $3.04 Million - $3.31 Million
41,064 Added 12.94%
358,522 $26.9 Million
Q2 2023

Aug 11, 2023

BUY
$76.01 - $86.7 $4.02 Million - $4.59 Million
52,935 Added 20.01%
317,458 $24.5 Million
Q1 2023

May 11, 2023

BUY
$77.31 - $88.08 $1.05 Million - $1.2 Million
13,576 Added 5.41%
264,523 $21.9 Million
Q4 2022

Feb 13, 2023

SELL
$62.32 - $89.47 $1.55 Million - $2.23 Million
-24,915 Reduced 9.03%
250,947 $21.5 Million
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $4.3 Million - $4.92 Million
72,281 Added 35.5%
275,862 $17 Million
Q2 2022

Aug 12, 2022

SELL
$57.72 - $65.01 $2.21 Million - $2.48 Million
-38,206 Reduced 15.8%
203,581 $12.6 Million
Q1 2022

May 13, 2022

BUY
$57.92 - $72.58 $3.91 Million - $4.9 Million
67,505 Added 38.73%
241,787 $14.4 Million
Q4 2021

Feb 10, 2022

BUY
$64.88 - $73.64 $2.05 Million - $2.33 Million
31,602 Added 22.15%
174,282 $12.7 Million
Q3 2021

Nov 10, 2021

BUY
$67.69 - $73.03 $1.49 Million - $1.61 Million
21,980 Added 18.21%
142,680 $9.97 Million
Q2 2021

Aug 10, 2021

SELL
$63.47 - $69.35 $922,472 - $1.01 Million
-14,534 Reduced 10.75%
120,700 $8.31 Million
Q1 2021

May 10, 2021

BUY
$60.0 - $68.46 $1.99 Million - $2.27 Million
33,187 Added 32.52%
135,234 $8.74 Million
Q4 2020

Feb 10, 2021

BUY
$56.65 - $64.55 $155,617 - $177,318
2,747 Added 2.77%
102,047 $5.95 Million
Q3 2020

Nov 13, 2020

BUY
$62.1 - $78.08 $1.14 Million - $1.44 Million
18,409 Added 22.76%
99,300 $6.28 Million
Q2 2020

Aug 07, 2020

BUY
$72.34 - $84.0 $1.63 Million - $1.89 Million
22,544 Added 38.64%
80,891 $6.22 Million
Q1 2020

May 15, 2020

SELL
$62.63 - $80.22 $4.46 Million - $5.72 Million
-71,270 Reduced 54.99%
58,347 $4.36 Million
Q4 2019

Feb 10, 2020

SELL
$61.62 - $67.78 $132,852 - $146,133
-2,156 Reduced 1.64%
129,617 $8.42 Million
Q3 2019

Nov 14, 2019

SELL
$62.51 - $69.0 $1.9 Million - $2.1 Million
-30,365 Reduced 18.73%
131,773 $8.35 Million
Q2 2019

Aug 09, 2019

BUY
$61.87 - $69.38 $3.13 Million - $3.51 Million
50,523 Added 45.27%
162,138 $11 Million
Q1 2019

May 15, 2019

BUY
$62.53 - $70.05 $5.36 Million - $6 Million
85,682 Added 330.4%
111,615 $7.26 Million
Q4 2018

Feb 11, 2019

SELL
$60.54 - $79.0 $111,514 - $145,518
-1,842 Reduced 6.63%
25,933 $1.62 Million
Q3 2018

Nov 09, 2018

BUY
$71.28 - $78.92 $99,649 - $110,330
1,398 Added 5.3%
27,775 $2.15 Million
Q2 2018

Aug 14, 2018

BUY
$64.88 - $75.68 $391,485 - $456,653
6,034 Added 29.66%
26,377 $1.87 Million
Q1 2018

May 15, 2018

BUY
$72.84 - $88.8 $38,678 - $47,152
531 Added 2.68%
20,343 $1.53 Million
Q4 2017

Feb 14, 2018

BUY
$71.15 - $83.52 $58,912 - $69,154
828 Added 4.36%
19,812 $1.42 Million
Q3 2017

Nov 13, 2017

BUY
$72.11 - $85.47 $1.37 Million - $1.62 Million
18,984
18,984 $1.54 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.